FDA Approves Supplemental New Drug Application for Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII

Adlon Therapeutics L.P. Announces Publication of Data from Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Studies Examining Sleep Quality Outcomes in CNS Drugs

Adlon Therapeutics L.P. Announces Two New Publications of Adhansia XR^® (methylphenidate HCl) Extended-Release Capsules CII Data

Adlon Therapeutics L.P. and the Prescription Drug Safety Network Launch New Resources to Encourage Safe and Responsible Use of Prescription Stimulant Medications

Adlon Therapeutics L.P. Announces Publication of Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Study Data in the Journal of Attention Disorders

Adlon Therapeutics Secures Adhansia XR™ (methylphenidate HCI) Extended Release Capsules CII Formulary Coverage from Express Scripts

Adlon Therapeutics L.P. and Purdue Pharma L.P. Will Present Data from Adhansia XR™ (methylphenidate HCl) Studies Examining Sleep Quality Outcomes, Functional Outcomes and Executive Functioning at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting

Adlon Therapeutics L.P. and Purdue Pharma L.P. to Present Six Scientific Posters at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting